Methyl 8-methoxy-1,4-dioxaspiro[4.5]decane-8-carboxylate is a heterocyclic intermediate typically used in the prepartion of BLU-667 as a potent and selective inhibitor of RET mutations, fusions, and predicted resistant mutants.
Precision Targeted Therapy with BLU-667 for RET-Driven Cancers. 
Landscape of Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired RET Fusion. 
 V.Subbiah, et al, Cancer Discov., 2018, 8(7), pp 836-849.
 Z.Piotrowska, et al, Cancer Discov., 2018, 8(12), pp 1529-1539.
NONH for all modes of transport
1. Product Specification
2. Safety Data Sheet
Please inquire for pricing and availability of this product by writing email email@example.com.